The effect of warfarin on blood viscosity in patients with ischemic stroke

Chonbuk National University Hospital0 个研究点目标入组 60 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•Male or female subjects with treatment-naïve non-valvular atrial fibrillation as evidenced by documented ECG evidence.
•o Female subjects of childbearing potential must be abstinent or practicing methods of birth control which are recognized as effective.
•o Females of childbearing potential must have a negative serum ß-hCG pregnancy test prior to study enrollment.
•Subject has a CHADS2 stroke risk score of 2 or greater and is eligible for warfarin therapy.
•o Congestive heart failure, hypertension, age of 75 years or greater, and diabetes each get 1 point towards the risk score. A previous stroke, transient ischemic attack, or thromboembolism gets 2 points.
•Subject is between 18 and 90 years of age.
•Subject is willing to comply with the requirements of the study protocol.
•Subject has given written informed consent to participate in the study.

•Subject is pregnant or breast-feeding.
•Subject has transient atrial fibrillation caused by a reversible condition (i.e. thyrotoxicosis, post-surgery)
•Subject has an active infection such as endocarditis.
•Subject has active internal bleeding or history of a condition associated with increased bleeding risk.
•Subject has an anemia.
•Subject has given blood or received a blood transfusion at any point during the study.
•Subject has concurrent hyperthyroidism.
•Patient has polycythemia vera or any hyperviscosity syndrome.
•Platelet count <90,000/µL at initial screening.
•Subject has poor diabetes or hypertension control (sustained systolic blood pressure = 180 mmHg or diastolic blood pressure = 100 mmHg).
•Subject has mitral stenosis or mechanical heart valves.
•Subject is taking steroids.
•Subject has a history of severe liver disease or end-stage renal disease receiving dialysis (HD or PD) or KT.
•Family members or employees of the investigator or study centers involved in the study.

发起方